BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Locatelli F, Reigner B. C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opinion on Investigational Drugs 2007;16:1649-61. [DOI: 10.1517/13543784.16.10.1649] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Sasaki Y, Noguchi-sasaki M, Matsuo-tezuka Y, Matsumoto-omori Y, Kurasawa M, Yorozu K, Shimonaka Y. Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice. Int J Hematol 2014;99:561-9. [DOI: 10.1007/s12185-014-1554-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
2 Aizawa K, Kawasaki R, Tashiro Y, Shimonaka Y, Hirata M. Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease. BMC Nephrol 2018;19:19. [PMID: 29374477 DOI: 10.1186/s12882-018-0818-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Serizawa K, Yogo K, Tashiro Y, Aizawa K, Kawasaki R, Hirata M, Endo K. Epoetin beta pegol prevents endothelial dysfunction as evaluated by flow-mediated dilation in chronic kidney disease rats. Eur J Pharmacol 2015;767:10-6. [PMID: 26432688 DOI: 10.1016/j.ejphar.2015.09.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
4 Kazory A, Ross EA. Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol 2009;53:639-47. [PMID: 19232895 DOI: 10.1016/j.jacc.2008.10.046] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
5 Koury MJ. Tracking erythroid progenitor cells in times of need and times of plenty. Experimental Hematology 2016;44:653-63. [DOI: 10.1016/j.exphem.2015.10.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
6 Aizawa K, Kawasaki R, Tashiro Y, Hirata M, Endo K, Shimonaka Y. Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase. Int J Hematol 2016;104:182-9. [DOI: 10.1007/s12185-016-2000-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Aizawa K, Tashiro Y, Hirata M, Takeda S, Kawasaki R, Endo K. Renoprotective effect of epoetin beta pegol by the prevention of M2 macrophage recruitment in Thy-1 rats. J Nephrol 2014;27:395-401. [PMID: 24821659 DOI: 10.1007/s40620-014-0099-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
8 Serizawa K, Yogo K, Tashiro Y, Kawasaki R, Endo K, Shimonaka Y, Hirata M. Epoetin beta pegol ameliorates flow-mediated dilation with improving endothelial nitric oxide synthase coupling state in nonobese diabetic rats. Cardiovasc Ther 2017;35. [PMID: 28054454 DOI: 10.1111/1755-5922.12250] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Bouman-Thio E, Franson K, Miller B, Getsy J, Cohen A, Bai SA, Yohrling J, Frederick B, Marciniak S, Jiao Q, Jang H, Davis H, Burggraaf J. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol 2008;48:1197-207. [PMID: 18812609 DOI: 10.1177/0091270008322907] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
10 Doshi S, Perez-ruixo JJ, Jang GR, Chow AT. Pharmacokinetics of erythropoiesis-stimulating agents. In: Elliott SG, Foote MA, Molineux G, editors. Erythropoietins, Erythropoietic Factors, and Erythropoiesis. Basel: Birkhäuser; 2009. pp. 199-223. [DOI: 10.1007/978-3-7643-8698-6_12] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Furukawa T, Okada K, Abe M, Tei R, Oikawa O, Maruyama N, Maruyama T. Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage. Int J Mol Sci 2015;16:30181-9. [PMID: 26694377 DOI: 10.3390/ijms161226229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Oh J, Joo KW, Chin HJ, Chae DW, Kim SG, Kim SJ, Chung W, Kim S, Huh W, Oh HY, Choi BS, Yang CW, Kim S. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis. J Korean Med Sci 2014;29:76-83. [PMID: 24431909 DOI: 10.3346/jkms.2014.29.1.76] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Aizawa K, Takeda S, Tashiro Y, Yorozu K, Hirata M, Kanada H, Moriguchi Y, Endo K. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome. Am J Nephrol 2012;36:419-26. [PMID: 23128049 DOI: 10.1159/000343493] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
14 Wojchowski DM, Sathyanarayana P, Dev A. Erythropoietin receptor response circuits. Curr Opin Hematol 2010;17:169-76. [PMID: 20173635 DOI: 10.1097/MOH.0b013e328338008b] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 0.6] [Reference Citation Analysis]
15 Nishizawa K, Yano T, Tanno M, Miki T, Kuno A, Tobisawa T, Ogasawara M, Muratsubaki S, Ohno K, Ishikawa S, Miura T. Chronic Treatment With an Erythropoietin Receptor Ligand Prevents Chronic Kidney Disease–Induced Enlargement of Myocardial Infarct Size. Hypertension 2016;68:697-706. [DOI: 10.1161/hypertensionaha.116.07480] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Leypoldt JK, Loghman-Adham M, Jordan P, Reigner B. Effect of hemodialysis and hemofiltration on plasma C.E.R.A. concentrations. Hemodial Int 2012;16:20-30. [PMID: 22098670 DOI: 10.1111/j.1542-4758.2011.00634.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Reverter-branchat G, Ventura R, Ezzel Din M, Mateus J, Pedro C, Segura J. Detection of erythropoiesis-stimulating agents in a single dried blood spot. Drug Test Anal 2018;10:1496-507. [DOI: 10.1002/dta.2418] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
18 Vogel M, Blobel M, Thomas A, Walpurgis K, Schänzer W, Reichel C, Thevis M. Isolation, Enrichment, and Analysis of Erythropoietins in Anti-Doping Analysis by Receptor-Coated Magnetic Beads and Liquid Chromatography–Mass Spectrometry. Anal Chem 2014;86:12014-21. [DOI: 10.1021/ac5024765] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
19 Moreno López R, Sicilia Aladrén B, Gomollón García F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol 2009; 15(37): 4675-4685 [PMID: 19787831 DOI: 10.3748/wjg.15.4675] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
20 Suzuki N, Yamamoto M. Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis. Pflugers Arch 2016;468:3-12. [PMID: 26452589 DOI: 10.1007/s00424-015-1740-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
21 Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68:1139-56. [PMID: 18484803 DOI: 10.2165/00003495-200868080-00009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]